文献速递骨软组织肉瘤与黑色素瘤妇科肿瘤支持与姑息治疗

支持双免疫治疗泛瘤种报销的论证

The case for tumour-agnostic reimbursement of dual immunotherapy.
PubMed 文献 · Eur J Cancer · 2026-05-05

本文回应Barjesteh van Waalwijk van Doorn-Khosrovani等对澳大利亚纳武利尤单抗联合伊匹木单抗泛瘤种报销的质疑,支持广泛覆盖。作者指出罕见及超罕见癌症患者存在严重未满足需求,部分患者可从免疫治疗显著获益。PBAC于2025年提出基于临床判断和最佳证据处方,2026年1月对帕博利珠单抗做出类似推荐。

要点

  • PBAC推荐基于临床判断和最佳证据使用纳武利尤单抗联合伊匹木单抗。
  • 罕见及超罕见癌症患者存在严重未满足需求,部分对免疫治疗敏感。
  • SWOG DART试验显示纳武利尤单抗联合伊匹木单抗在多种组织学类型中有临床意义活性。

核心结论

  • 支持PBAC对纳武利尤单抗联合伊匹木单抗的泛瘤种报销推荐,认为临床判断不应被完美证据要求所阻碍。

主要发现

  • SWOG DART试验是纳武利尤单抗联合伊匹木单抗在罕见/超罕见癌症中最大规模的前瞻性评估,在多种组织学类型中显示有临床意义的活性,且未进行生物标志物选择。
  • 部分转移性疾病患者在治疗后多年保持无病状态,这在难治性背景下化疗或支持治疗中很少实现。

关键数值与推荐

  • PBAC于2025年提出纳武利尤单抗联合伊匹木单抗的处方应由临床判断和最佳证据指导,适用于未定义的「免疫治疗敏感」晚期或转移性癌症。
  • PBAC于2026年1月对帕博利珠单抗做出类似推荐。

临床怎么用

  • 对于罕见及超罕见癌症患者,可基于临床判断和最佳证据使用纳武利尤单抗联合伊匹木单抗,无需生物标志物选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Barjesteh van Waalwijk van Doorn-Khosrovani and colleagues raise important questions about this recommendation for tumour-agnostic reimbursement of nivolumab and ipilimumab in Australia. We respectfully offer a counterpoint and endorse the broad coverage. In 2025, Pharmaceutical Benefits Advisory Committee (PBAC) proposed that prescribing nivolumab and ipilimumab be guided by clinical judgement informed by the best available evidence for undefined "immunotherapy-sensitive" advanced or metastatic cancers, and, in January 2026 made a similar recommendation for pembrolizumab. Patients with rare and ultra-rare cancers, including but not limited to angiosarcoma, alveolar soft part sarcoma, gestational trophoblastic disease, small cell carcinoma of the ovary (hypercalcemic type), and adrenocortical carcinoma, face profound unmet need. Within many of these diseases, a subset of patients derives substantial benefit from immunotherapy. For example, the SWOG DART (Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors) trial, the largest prospective evaluation of nivolumab plus ipilimumab in rare/ultra-rare cancers, demonstrated clinically meaningful activity across multiple histologies, without biomarker selection. Notably, some patients with metastatic disease remain disease-free years after treatment, outcomes rarely achieved with chemotherapy or supportive care in refractory settings. Therefore, concerns that biomarker-agnostic approval signals an evidentiary retreat overlook both our incomplete understanding immune sensitivity and the global access limits to comprehensive genomic testing. Importantly, clinical judgement is not arbitrary; it reflects training, experience, ethical reasoning, and patient-centred decision making. The question is whether demanding perfect evidence should prevent access to potentially transformative treatment. Grounded in evidence and expertise, PBAC's decision prioritises meaningful access to effective therapy for patients with few alternatives.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Subbiah V, Kurzrock R. The case for tumour-agnostic reimbursement of dual immunotherapy. Eur J Cancer. 2026. PMID: 42106259. doi:10.1016/j.ejca.2026.116784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。